The possibility for clinical cardiovascular (CV) incidents was decreased by 50% for patients with rigorous heart failure getting a ground-breaking genetically targeted enzyme replacement treatment against placebo, reports the CUPID study submitted at the Heart Failure Congress 2010, arranged by the Heart Failure Association of the European Society of Cardiology, in Berlin.

Moreover, the phase II study revealed that patients cured with MYDICARr, particularly those getting the maximum dosage, performed better in potentially described endpoints in the symptomatic and functional fields of heart failure, together with positive impacts on biomarker levels and cardiac remodeling.

Professor Barry H Greenberg, the presenter of the trial from University of California San Diego said that the findings offer the first placebo restricted proof of effectiveness for MYDICARr and posed no security fears. These results present robust support for progression to Phase III studies utilizing huge number of patients carried out over stretched time periods.

Barry added, "MYDICARr has the potential to change the treatment landscape for patients with severe heart failure by offering us a new tool in the box".

He said that the new therapies are especially required for this set of patients who have annual deaths of 10 to 20%, or higher.